Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | PPM1D | O15297 | 1/20 | 0.30 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22375302 | 1.00 | GAA (0.35) | GAASMN1; SMN2KCNA5PPM1DSLC18A3 | |
| SCHEMBL22375301 | 1.00 | GAA (0.35) | GAASMN1; SMN2KCNA5PPM1DSLC18A3 | |
| SCHEMBL16746020 | 1.00 | GAA (0.35) | GAASMN1; SMN2KCNA5PPM1DSLC18A3 | |
| SCHEMBL22375300 | 0.95 | GAA (0.35) | GAASMN1; SMN2KCNA5PPM1D | |
| SCHEMBL16746024 | 0.95 | GAA (0.35) | GAASMN1; SMN2KCNA5PPM1D | |
| SCHEMBL22375299 | 0.95 | GAA (0.35) | GAASMN1; SMN2KCNA5PPM1D | |
| SCHEMBL16746021 | 0.95 | GAA (0.35) | GAASMN1; SMN2KCNA5PPM1D | |
| SCHEMBL16746015 | 0.74 | KCNA5 (0.50) | GAASMN1; SMN2KCNA5SLC18A3 | |
| SCHEMBL26014606 | 0.74 | KCNA5 (0.50) | GAASMN1; SMN2KCNA5SLC18A3 | |
| SCHEMBL26014617 | 0.74 | KCNA5 (0.50) | GAASMN1; SMN2KCNA5SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148525-A1 | METHODS OF INCORPORATING AN AMINO ACID COMPRISING A BCN GROUP INTO A POLYPEPTIDE USING AN ORTHOGONAL CODON ENCODING IT AND AN ORTHORGONAL PYLRS SYNTHASE | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148525-A1 | METHODS OF INCORPORATING AN AMINO ACID COMPRISING A BCN GROUP INTO A POLYPEPTIDE USING AN ORTHOGONAL CODON ENCODING IT AND AN ORTHORGONAL PYLRS SYNTHASE | BCAT1, BCDIN3D, YARS1 | GAA 2812/4885SMN1; SMN2 4059/4885KCNA5 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.